Key Trends Shaping the Future Dengue Vaccine Market From 2025-2034: Advancements In Dengue Tetravalent Vaccines Enhance Comprehensive Protection Against All Serotypes

Which drivers are expected to have the greatest impact on the over the dengue vaccine market's growth?
The increasing incidence of dengue fever is expected to drive the growth of the dengue vaccine market moving forward. Dengue fever is a viral infection transmitted by Aedes aegypti mosquitoes, causing symptoms like high fever, headaches, joint pain, and rashes. The rise in dengue cases is primarily due to climate change, urbanization, insufficient mosquito control, and viral evolution. The dengue vaccine works by stimulating the immune system to identify and combat the virus, reducing the severity of infections and lowering the risk of severe complications, which helps decrease cases and hospitalizations. For example, in May 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that dengue cases in the Americas surpassed 7 million in April 2024, an increase from 4.6 million in 2023. As a result, the growing number of dengue fever cases is driving the growth of the dengue vaccine market.

Get Your Dengue Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report

What is the future CAGR of the dengue vaccine market, and how will it impact industry expansion?
The dengue vaccine market has expanded rapidly, projected to grow from $0.64 billion in 2024 to $0.72 billion in 2025 at a CAGR of 12.4%. Growth has been fueled by increasing urbanization, rising demand for effective vaccines, greater foreign travel exposure, expanding healthcare services, and mass vaccination efforts.

The dengue vaccine market is forecasted to grow significantly, reaching $1.14 billion by 2029 at a CAGR of 12.3%. Growth is fueled by the rising incidence of dengue, increased initiatives from various organizations, ongoing clinical trials, and a greater focus on multi-strain and tetravalent vaccine formulations. Key trends include a growing demand for preventive vaccines, advancements in vaccine technology, the development of combination vaccines, increased research and clinical trials for new vaccine candidates, and efforts to enhance vaccine efficacy and safety.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

What are the most significant trends transforming the dengue vaccine market today?
In the dengue vaccine market, companies are focusing on developing tetravalent vaccines to protect against all four dengue virus serotypes. In December 2022, Takeda Pharmaceutical Company received approval for QDENGA, a dengue vaccine that provides comprehensive protection and lasts about 4.5 years, demonstrating efficacy in preventing hospitalizations from dengue.

Which key market segments comprise the dengue vaccine market and drive its revenue growth?
The dengue vaccinemarket covered in this report is segmented -

1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users

Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19026

What regions are at the forefront of dengue vaccine market expansion?
Asia-Pacific was the largest region in the dengue vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the dengue vaccine market?
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

What Is Covered In The Dengue Vaccine Global Market Report?

•Market Size Forecast: Examine the dengue vaccine market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the dengue vaccine market for a structured understanding.
•Key Players Overview: Analyze major players in the dengue vaccine market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the dengue vaccine market.
•Segment Contributions: Evaluate how different segments drive overall growth in the dengue vaccine market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the dengue vaccine market.
•Industry Challenges: Identify potential risks and obstacles affecting the dengue vaccine market.
•Competitive Landscape: Review strategic developments in the dengue vaccine market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.